| Obesity and cancer risk: Emerging biological mechanisms and perspectives KI Avgerinos, N Spyrou, CS Mantzoros, M Dalamaga Metabolism 92, 121-135, 2019 | 1393 | 2019 |
| Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials KI Avgerinos, N Spyrou, KI Bougioukas, D Kapogiannis Experimental gerontology 108, 166-173, 2018 | 185 | 2018 |
| The role of adipokines in breast cancer: current evidence and perspectives GS Christodoulatos, N Spyrou, J Kadillari, S Psallida, M Dalamaga Current obesity reports 8, 413-433, 2019 | 95 | 2019 |
| Classic and novel adipocytokines at the intersection of obesity and cancer: diagnostic and therapeutic strategies N Spyrou, KI Avgerinos, CS Mantzoros, M Dalamaga Current obesity reports 7, 260-275, 2018 | 79 | 2018 |
| Gender differences in obesity-related cancers G Argyrakopoulou, M Dalamaga, N Spyrou, A Kokkinos Current obesity reports 10, 100-115, 2021 | 70 | 2021 |
| Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion-and salience-related changes correlate with weight loss effects: a 4 … OM Farr, J Upadhyay, A Gavrieli, M Camp, N Spyrou, H Kaye, H Mathew, ... Diabetes 65 (10), 2943-2953, 2016 | 64 | 2016 |
| Body fatness associations with cancer: evidence from recent epidemiological studies and future directions SC Larsson, N Spyrou, CS Mantzoros Metabolism 137, 155326, 2022 | 61 | 2022 |
| Management of venous thromboembolism in pregnancy DR Kalaitzopoulos, A Panagopoulos, S Samant, N Ghalib, J Kadillari, ... Thrombosis research 211, 106-113, 2022 | 60 | 2022 |
| The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era N Spyrou, N Vallianou, J Kadillari, M Dalamaga Seminars in Cancer Biology 73, 356-376, 2021 | 49 | 2021 |
| Could the endocrine disruptor bisphenol-A be implicated in the pathogenesis of oral and oropharyngeal cancer? Metabolic considerations and future directions R Emfietzoglou, N Spyrou, CS Mantzoros, M Dalamaga Metabolism 91, 61-69, 2019 | 34 | 2019 |
| Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges G Papavasileiou, D Tsilingiris, N Spyrou, NG Vallianou, I Karampela, ... Seminars in Cancer Biology 91, 70-98, 2023 | 27 | 2023 |
| Effective treatment of low-risk acute GVHD with itacitinib monotherapy A Etra, A Capellini, A Alousi, MM Al Malki, H Choe, Z DeFilipp, WJ Hogan, ... Blood, The Journal of the American Society of Hematology 141 (5), 481-489, 2023 | 24 | 2023 |
| Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD Y Akahoshi, N Spyrou, WJ Hogan, F Ayuk, Z DeFilipp, D Weber, HK Choe, ... Blood Advances 7 (16), 4479-4491, 2023 | 23 | 2023 |
| Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification A Etra, S Gergoudis, G Morales, N Spyrou, J Shah, S Kowalyk, F Ayuk, ... Blood Advances 6 (12), 3707-3715, 2022 | 21 | 2022 |
| Obesity and leukemia: biological mechanisms, perspectives, and challenges D Tsilingiris, NG Vallianou, N Spyrou, D Kounatidis, GS Christodoulatos, ... Current obesity reports 13 (1), 1-34, 2024 | 13 | 2024 |
| Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease MM Al Malki, K London, J Baez, Y Akahoshi, WJ Hogan, A Etra, H Choe, ... Blood Advances 7 (17), 5189-5198, 2023 | 13 | 2023 |
| Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs G Asimomitis, AG Deslauriers, AG Kotini, E Bernard, D Esposito, ... Blood Advances 6 (10), 2992-3005, 2022 | 13 | 2022 |
| The utility of biomarkers in acute GVHD prognostication N Spyrou, Y Akahoshi, F Ayuk, E Holler, H Choe, A Etra, WJ Hogan, ... Blood Advances 7 (17), 5152-5155, 2023 | 11 | 2023 |
| Management of hematologic malignancies in the era of COVID-19 pandemic: pathogenetic mechanisms, impact of obesity, perspectives, and challenges D Tsilingiris, N Nasiri-Ansari, N Spyrou, F Magkos, M Dalamaga Cancers 14 (10), 2494, 2022 | 9 | 2022 |
| Acute GVHD: New approaches to clinical trial monitoring N Spyrou, JE Levine, JLM Ferrara Best Practice & Research Clinical Haematology 35 (4), 101400, 2022 | 7 | 2022 |
